More Men at Low Risk of Prostate Cancer Choosing to Avoid Treatment

More Men at Low Risk of Prostate Cancer Choosing to Avoid Treatment

An increasing number of men at low risk of developing prostate cancer are choosing a wait-and-see approach in lieu of treatment options such as radiation or surgery.

In 2010, 14.5% of men with low-risk prostate cancer used a wait-and-see approach, also known as active surveillance. By 2015, that figure was 42.1%, according to new research published in JAMA. Over the same period, the rate of men in this group having their prostate gland removed declined from 47% to 31%, while those who received radiation therapy declined from 38% to 26%.

Among men with intermediate risk, the active surveillance rate increased from 5.8% to 9.6% over the time period. The percentage of men in this group having either their prostate removed or having radiation only hardly declined. Among men with high risk, the rate of active surveillance remained the same, at about 2% over the period. Having a prostatectomy increased from 38% to 43%, while radiation therapy decreased from 60% to 55%.

The results of the study are not all that surprising, considering that in 2010 the National Comprehensive Cancer Network changed its guidelines, recommending active surveillance for men at low risk or those with a short life expectancy.

Prostate cancer is the second most common cancer among men worldwide. Last year, 1.3 million new cases were diagnosed.


Jonathan Block

Jonathan Block

Jonathan Block is an associate editor at BioCentury, which provides news and information about the biotechnology and pharmaceutical industries. Prior to joining BioCentury in 2019, Jonathan worked for MedShadow as content editor. He has been an editor and writer for multiple pharmaceutical, health and medical publications, including The Pink Sheet, Modern Healthcare, Health Plan Week and Psychiatry Advisor. He holds a BA from Tufts University and is earning an MPH with a focus on health policy from the CUNY Graduate School of Public Health & Health Policy.


Did you find this article helpful?


Latest News

Breaking News – EpiPen Malfunction

Breaking News – EpiPen Malfunction

Just released from the FDA – Pfizer has informed the FDA that they are aware of several continuing problems that people are having using the EpiPen (epinephrine) and EpiPen Jr (epinephrine) auto-injectors and generic versions. Some of the problems are from user error and some from EpiPen malfunction. Here are…

ACE Inhibitors in the Time of Coronavirus

ACE Inhibitors in the Time of Coronavirus

Are you worried about ACE inhibitors and coronavirus? You may be hearing that one of the entry methods for the coronavirus in humans is by attaching to the ACE-2 enzyme. This has raised alarms among those with heart disease who use ACE inhibitors (with names ending in -pril, such as…

  • Advertisement